Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.
In 2019, the hajj will take place between 9 and 14 August. The risk for EU/EEA citizens to become infected with communicable diseases during the 2019 hajj is considered low, thanks to the vaccination requirements for travelling to Makkah (Mecca) and the Saudi Arabian preparedness plans that address the management of health hazards during and after hajj.
The objective of this report is to systematically review the evidence on active case finding in prison settings, with a focus on the European Union (EU) and the European Economic Area (EEA) region.
ECDC conducted a systematic review of the literature published between 2005–2015, with the aim to estimate the prevalence of hepatitis B and C in the general population and specific population subgroups in the EU/EEA Member States. This review is an update of an earlier review covering the period 2000–2009.
Illnesses caused by infectious diseases are common in children in schools or other childcare settings. Currently there is no common EU approach to the control of communicable diseases in schools or other childcare settings, and existing information is uncertain.
This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.
Early in 2015, a shortage of acellular pertussis-containing vaccines was brought to the attention of ECDC. This risk assessment provides a detailed list of mitigation options available to Member States.
This risk assessment was triggered by two cases of paralytic poliomyelitis in children, caused by circulating vaccine-derived poliovirus type 1 (cVDPV1) in Ukraine during June and July 2015.
This rapid risk assessment examines the implications of the temporary recommendations for EU Member States and assesses whether the developments leading to the declaration of a PHEIC represent an increased risk of WPV importation to Member States of the European Union.
The confirmed circulation of wild-type poliovirus (WPV) in Israel and the outbreak of poliomyelitis in Syria mean that there is a high risk the disease will be reintroduced into the EU/EEA.